

# Max Financial Services

Estimate change	
TP change	
Rating change	

Bloomberg	MAXF IN
Equity Shares (m)	345
M.Cap.(INRb)/(USDb)	461.8 / 5.4
52-Week Range (INR)	1351 / 864
1, 6, 12 Rel. Per (%)	7/4/26
12M Avg Val (INR M)	1171

Financials & Valuations (INR b)			
Y/E MARCH	FY25	FY26E	FY27E
Gross Premium	332.2	381.8	438.9
PAT	4.0	7.1	9.3
APE	87.7	102.4	118.8
VNB margin (%)	24.0	25.0	25.5
Op. RoEV (%)	19.1	18.5	18.4
AUM (INRb)	1,750	1,933	2,180
VNB(INRb)	21.1	25.3	30.0
EV per Share	584	698	831
Valuations			
P/EV (x)	2.9	2.4	2.0
P/EVOP (x)	19.4	15.6	13.1

Shareholding Pattern (%)			
As On	Mar-25	Dec-24	Mar-24
Promoter	1.7	3.3	6.5
DII	47.3	42.7	39.9
FII	44.8	47.5	47.7
Others	6.2	6.5	5.9

FII includes depository receipts

**CMP: INR1,338**      **TP: INR1,330 (-1%)**      **Neutral**

## Strong margin performance, reverse merger key to re-rating

- Axis Max Life Insurance (MAXLIFE) continued to report better-than-industry performance in 4QFY25, with new business APE growth of 6% YoY to INR30.4b (in line). For FY25, it came in at INR87.7b, up 21% YoY.
- MAXLIFE reported 4% YoY growth in VNB to INR8.5b (8% beat), resulting in VNB margin of 28% vs. 28.6% in 4QFY24 (MOFSLe: 25.8%), as the focus shift to higher-margin traditional products led to strong sequential improvement.
- The company reported EV of INR252b as of FY25 end, reflecting strong operating RoEV of 19.1%.
- Management aims to achieve 300bp-400bp alpha over private industry premium growth, with improvement in VNB margin to 24-25% in FY26.
- We have slightly raised our VNB estimates, factoring in higher business from traditional products. We expect 25%/25.5% VNB margin in FY26E/FY27E and keep APE estimates unchanged. **Reiterate Neutral** with a TP of INR1,330, premised on 2x FY27E EV and a holding company discount of 20%. The success of the reverse merger is key for further re-rating of the stock.

## Sequential improvement in VNB margin as ULIP contribution declines

- Gross premium income grew 11% YoY to INR118.6b (in line). Renewal premium grew 16% YoY to INR77.8b (in line). For FY25, GWP came in at INR332.2b, up 13% YoY.
- ULIP contribution declined to 40% in 4QFY25 from 44%/45% in 2QFY25/3QFY25, while par/non-par savings contribution increased sequentially to 19%/28% from 16%/26% in 3QFY25. Combined with the increase in the rider attachment ratio (43% in FY25 vs. 34% in FY24), the product mix shift resulted in 480bp sequential improvement in VNB margin.
- MAXLIFE launched two products during the quarter - Smart Term Plan Plus (Term product) and Smart Term with Additional Returns (ULIP product), which have higher sum assured multiples and contribute toward achieving higher margin.
- On the distribution front, proprietary /bancassurance channels grew 1%/10% YoY. Proprietary channel witnessed 26% YoY growth in FY25, aided by 16% YoY growth in offline channel and 57% YoY growth in online channel due to higher ULIP sales in e-commerce on the back of new fund offers. Bancassurance channel grew 12% YoY in FY25 as a continued slowdown in Axis Bank channel (+10% YoY) was offset by strong growth in other banca partnerships (+27% YoY).
- The policyholder expense to GWP declined 24bp YoY to 13.6% in FY25.
- Persistency on the NOP basis improved across almost all cohorts, particularly in the 37th-month (up 400bp YoY to 68%) and 49th-month (up 300bp YoY to 60%).
- AUM grew 16% YoY to INR1.75t, while solvency improved to 201%.

**Research Analyst: Prayesh Jain** (Prayesh.Jain@MotilalOswal.com) | **Nitin Aggarwal** (Nitin.Aggarwal@MotilalOswal.com)

**Research Analyst: Kartikeya Mohata** (Kartikeya.Mohata@MotilalOswal.com) | **Muskan Chopra** (Muskan.Chopra@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

### Highlights from the management commentary

- The company expects more clarity on the reverse merger after changes in the Insurance Act, expected in the monsoon session of Parliament after which an immediate action will be taken.
- Management wants to increase brand awareness of Axis Max Life in Tier-2/3 cities. Decisions about pricing would be taken next year when Axis Max life brand will cross one year of existence.
- Data and integration are key differentiators in the e-commerce channel and the company expects the growth momentum to continue with some impact of high base, going forward.

### Valuation and view

- MAXLIFE reported a steady performance in APE in 4QFY25, which was in line with our estimates. Strong growth momentum continued in the proprietary channel, driven by secular growth in online sales, agency, and direct selling. The decline in share of ULIPs, higher rider attachment and innovative traditional products resulted in VNB margin improvement in 4QFY25.
- We have slightly raised our VNB estimates, factoring in higher business from traditional products. We expect 25%/25.5% VNB margin for FY26E/27E and keep APE estimates intact. **Reiterate Neutral** with a TP of INR1,330, premised on 2x FY27E EV and a holding company discount of 20%. Further re-rating of the stock will be driven by any developments on the reverse merger.

### Quarterly Snapshot

Policy holder's A/c (INR b)	FY24				FY25				FY24	FY25	FY25E 4QE	A v/s E	
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q					
First year premium	9.9	15.3	17.6	25.4	12.6	20.5	20.4	29.8	68.9	83.3	29.2	2%	
Growth (%)	8.0%	37.7%	20.7%	5.3%	27.1%	33.6%	16.1%	17.3%	16.8%	20.9%	15.1%		
Renewal premium	30.1	42.0	46.1	66.8	33.2	47.2	52.2	77.8	185.1	210.5	75.3	3%	
Growth (%)	15.1%	7.5%	14.6%	14.6%	10.3%	12.4%	13.3%	16.4%	13.0%	13.7%	12.7%		
Single premium	8.7	8.9	9.3	15.2	8.2	9.7	9.6	11.1	41.3	38.5	13.7	-19%	
Growth (%)	52.8%	14.2%	15.5%	66.5%	-5.7%	8.4%	3.0%	-27.0%	35.1%	-7.0%	-9.8%		
<b>Gross premium income</b>	<b>48.7</b>	<b>66.3</b>	<b>73.0</b>	<b>107.4</b>	<b>54.0</b>	<b>77.4</b>	<b>82.2</b>	<b>118.6</b>	295.3	332.2	<b>118.2</b>	<b>0%</b>	
Growth (%)	18.7%	14.2%	16.1%	17.3%	10.8%	16.8%	12.7%	10.5%	16.5%	12.5%	10.1%		
<b>PAT</b>	<b>1.0</b>	<b>1.6</b>	<b>1.5</b>	<b>-0.5</b>	<b>1.6</b>	<b>1.4</b>	<b>0.7</b>	<b>0.4</b>	3.6	4.0	<b>1.7</b>	<b>-77%</b>	
Growth (%)	13.2%	196.2%	-34.9%	NA	51.4%	-11.2%	-53.8%	NA	-17.8%	12.1%			
<b>Key metrics (INRb)</b>													
New Business APE	11.1	16.5	18.0	28.7	14.5	21.7	21.1	30.4	72.5	87.7	30.4	0%	
Growth (%)	10.3%	38.8%	18.9%	13.2%	30.5%	31.3%	17.4%	5.8%	16.9%	20.9%	0.1		
VNB	2.5	4.2	4.9	8.2	2.5	5.1	4.9	8.5	19.7	21.1	7.9	8%	
Growth (%)	16.0%	11.5%	-17.5%	6.6%	2.8%	23.1%	0.0%	3.8%	1.2%	6.8%	0.0		
AUM	1,291.3	1,341.6	1,426.2	1,508.4	1,611.5	1,701.4	1,717.1	1,750.0	1,508.4	1,750.0	1,719	2%	
Growth (%)	20.5%	18.4%	20.5%	22.8%	24.8%	26.8%	20.4%	16.0%	22.8%	16.0%	0.1		
<b>Key Ratios (%)</b>													
VNB Margin (%)	22.2	25.2	27.2	28.6	17.5	23.6	23.2	28.0	42.2	24.0	25.8		

Policyholder A/c (INRb)	FY24				FY25				YoY (%)	QoQ (%)
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q		
<b>Gross premium</b>	<b>48.7</b>	<b>66.3</b>	<b>73.0</b>	<b>107.4</b>	<b>54.0</b>	<b>77.4</b>	<b>82.2</b>	<b>118.6</b>	<b>10</b>	<b>44</b>
First year premium	9.9	15.3	17.6	25.4	12.6	20.5	20.4	29.8	17	46
Renewal premium	30.1	42.0	46.1	66.8	33.2	47.2	52.2	77.8	16	49
Single premium	8.7	8.9	9.3	15.2	8.2	9.7	9.6	11.1	-27	16
<b>Shareholder PAT</b>	<b>1.0</b>	<b>1.6</b>	<b>1.5</b>	<b>-0.5</b>	<b>1.6</b>	<b>1.4</b>	<b>0.7</b>	<b>0.4</b>	<b>-175</b>	<b>-46</b>
<b>APE data (INRb)</b>										
PAR	1.9	3.9	3.3	4.3	1.9	2.1	3.5	5.7	34	65
Individual Protection	0.9	1.6	1.6	1.8	1.5	2.2	2.1	3.0	65	44
Group protection	1.2	1.0	1.0	0.5	1.5	1.1	0.9	0.9	81	5
Non Par Savings	4.2	4.6	6.2	10.2	3.9	6.6	5.5	8.5	-17	54
ULIP	2.8	5.5	5.8	11.9	5.7	9.5	9.4	12.2	3	29
<b>APE (% of total)</b>										
PAR	17.0	23.7	18.5	14.8	13.0	9.7	16.4	18.8	395	233
Individual Protection	8.0	9.7	9.0	6.4	10.0	10.0	10.0	10.0	359	0
Group protection	11.0	6.0	5.5	1.8	10.0	5.0	4.3	3.1	129	-117
Non Par Savings	38.0	28.0	34.5	35.6	27.0	30.3	26.3	28.0	-759	172
ULIP	25.0	33.4	32.5	41.4	39.0	44.0	44.7	40.1	-124	-460
<b>Distribution mix (%)</b>										
Proprietary	40.0	40.0	40.0	40.0	49.0	43.7	41.7	38.6	-139	-308
Banca	58.0	59.7	59.0	56.4	48.0	54.3	56.2	59.4	295	312
Others	2.0	0.3	1.0	3.6	2.0	2.0	2.1	2.0	-157	-4
<b>Key Ratios (%)</b>										
<b>Operating ratios</b>									<b>YoY (bp)</b>	
Opex to GWP ratio (%)	17.4	15.4	14.8	13.8	17.9	16.5	14.9	13.6	-20	-130
Solvency Ratio	188.0	184.0	179.0	172.0	203.0	198.0	196.0	201.0	2,900	500
<b>Profitability ratios</b>									<b>YoY (bp)</b>	
VNB margins	22.2	25.2	27.2	28.6	17.5	23.6	23.2	28.0	0	540
<b>Persistency ratios (%)</b>										
13th Month	84.0	84.0	85.0	87.0	87.0	87.0	85.0	88.0	100	300
25th Month	69.0	70.0	70.0	70.0	71.0	71.0	72.0	74.0	400	200
37th Month	52.0	62.0	63.0	61.0	64.0	64.0	64.0	63.0	200	-100
49th Month	64.0	65.0	65.0	58.0	67.0	67.0	67.0	57.0	-100	-1,000
61st Month	58.0	57.0	58.0	52.0	58.0	58.0	58.0	53.0	100	-500
<b>Key Metrics (INRb)</b>										
VNB	2.5	4.2	4.9	8.2	2.5	5.1	4.9	8.5	4	74
AUM	1,291	1,342	1,426	1508	1612	1701	1717	1750	16	2
Equity Mix (%)	26.5	28.1	30.1	29.1	29.7	43.3	29.5	27.6	-144	-191



## Highlights from the management commentary

### FY25 highlights

- Max Life reported 2-year CAGR of 18% in individual adjusted single premium, which is the fastest growth among the top-10 private insurers.
- The company did 80 product interventions in FY25 because of surrender guidelines. Two new products were launched in 4QFY25 - STAR ULIP and Smart Term Plan Plus.
- Rider attachment increased to 43% in FY25, which cushioned the impact of surrender regulations.
- VNB margin of 24% in FY25 was at the higher end of 23-24% guidance.
- Many product launches are planned in FY26, especially in the traditional space, to rebalance the product mix.
- No dividend payout to preserve capital and grow embedded value.
- The company expects more clarity on the reverse merger after changes in the Insurance Act, expected in the monsoon session of Parliament, after which an immediate action will be taken.

#### Product mix

- The company witnessed strong growth in Apr'25 with contribution from all lines of business.
- Various efforts have been made to rebalance the product mix, including new product launches and higher focus on traditional products, which will likely result in a decline in ULIP contribution in FY26.
- The company expects to achieve 300bp-400bp higher growth than private industry in FY26.
- Management wants to increase brand awareness of Axis Max Life in Tier-2/3 cities. Decisions about pricing would be taken next year when Axis Max Life brand will cross one year of existence.
- Protection is under penetrated in Top-25 cities and will continue to grow on the back of rider attachment. Protection is the top growth strategy for the company.

#### VNB margin

- The company expects margin to increase from 24% in FY25 to 24-25% in FY26, with demand for traditional products rising.
- The life insurance industry is looking at product categories that will give more margins to tackle margin pressure due to regulations.

#### Distribution


- No formal communication has happened about any regulatory changes related to the bancassurance channel.
- Axis Bank channel (48% of company's bancassurance business) witnessed 7% growth in 4QFY25 (10% in FY25), which mirrors the slow growth at the bank level and also impact of higher base. Overall bancassurance growth has slowed down for the industry as banks have focused on building deposits. Protection is becoming a key part of Axis Bank's portfolio, which will contribute to higher growth.
- The company has 54%/56% counter share at Yes Bank/Axis Bank.
- A strong 50% CAGR has been witnessed in e-commerce channel, with the company maintaining the top position for protection business in the e-commerce channel. The channel has started to participate in the savings business as well.
- Data and integration are key differentiators in the e-commerce channel and the company expects the growth momentum to continue with some impact of high base, going forward.
- New banca partnerships have seen strong traction on the back of enhanced distribution capabilities, training programs for salesforce and product innovation.

#### EV

- Positive impact of INR50m on operating variance was due to assumption recalibration with some positives on mortality and expense side and marginal negative on persistency and lapse side.


## Key exhibits

**Exhibit 1: First-year premium grew 17% YoY, while total premium grew 10% YoY in 4QFY25**




Sources: MOFSL, company reports

**Exhibit 2: Share of renewal premium increased to 66% in 4QFY25**




Sources: MOFSL, company reports

**Exhibit 3: Expense-to-GWP ratio stood at 14% for 12MFY25**




Sources: MOFSL, company reports

**Exhibit 4: VNB margin contracted 60bp YoY to 28%**




Sources: MOFSL, company reports

**Exhibit 5: Share of ULIP in total APE rose to 40% in 4QFY25**




Sources: MOFSL, company reports

**Exhibit 6: Trend in 13<sup>th</sup>/25<sup>th</sup>/61<sup>st</sup> month persistency**




Sources: MOFSL, company reports

**Exhibit 7: Share of protection stood at 13% of the total APE, while the share of ULIP declined to 40% in 4QFY25**




Sources: MOFSL, company reports

**Exhibit 8: Distribution mix (%)**




Sources: MOFSL, company reports

**Exhibit 9: Solvency ratio healthy at 201%, well above the regulatory requirement of 150%**



Sources: MOFSL, company reports

**Exhibit 10: One-year forward P/EV chart trend**



Sources: MOFSL, company reports

**Exhibit 11: We value MAXF at INR1,330 per share**

	Mar'27E
Appraisal value method (INR b)	
Embedded value	359
New business profit	30.0
Appraisal value	717
MFS stake post-deal	80%
MFS value	574
MFS valuation per share (INR)	1,663
Appraisal value-to-embedded value (x)	2.2
Holding company discount	20%
Target price (INR)	1,330
Upside/downside	-1%

Source: MOFSL

## Financials and valuations

Technical account (INR m)	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Gross Premiums	1,61,836	1,90,179	2,24,141	2,53,419	2,95,290	3,32,230	3,81,782	4,38,869
Reinsurance Ceded	2,049	2,788	4,272	4,601	5,443	6,124	7,037	8,089
Net Premiums	1,59,788	1,87,391	2,19,870	2,48,818	2,89,847	3,26,106	3,74,745	4,30,780
Income from Investments	21,589	1,21,657	87,408	60,936	1,70,875	1,33,732	1,36,385	1,53,442
Other Income	612	730	878	792	77	77	77	77
<b>Total income (A)</b>	<b>1,81,989</b>	<b>3,09,778</b>	<b>3,08,155</b>	<b>3,10,547</b>	<b>4,60,800</b>	<b>4,59,916</b>	<b>5,11,207</b>	<b>5,84,299</b>
Commission	(10,244)	(12,270)	(14,028)	(16,138)	(23,983)	(27,877)	(32,286)	(37,464)
Operating expenses	(23,441)	(27,008)	(30,192)	(35,808)	(40,861)	(46,581)	(53,103)	(60,537)
<b>Total commission and opex</b>	<b>(33,685)</b>	<b>(39,277)</b>	<b>(44,220)</b>	<b>(51,947)</b>	<b>(64,843)</b>	<b>(74,458)</b>	<b>(85,389)</b>	<b>(98,001)</b>
Benefits Paid (Net)	66,222	70,149	92,772	99,792	1,33,212	1,35,368	1,50,651	1,73,778
Chg in reserves	66,394	1,96,686	1,64,581	1,50,603	2,57,486	2,41,803	2,65,264	3,00,189
Prov for doubtful debts								
<b>Total expenses (B)</b>	<b>1,69,073</b>	<b>3,08,010</b>	<b>3,03,993</b>	<b>3,04,550</b>	<b>4,57,656</b>	<b>4,53,739</b>	<b>5,03,434</b>	<b>5,74,117</b>
<b>(A) - (B)</b>	<b>12,916</b>	<b>1,768</b>	<b>4,162</b>	<b>5,997</b>	<b>3,144</b>	<b>6,177</b>	<b>7,773</b>	<b>10,182</b>
Prov for Tax	-	-	-	-	-	-	-	-
<b>Surplus / Deficit</b>	<b>12,916</b>	<b>1,768</b>	<b>4,162</b>	<b>5,997</b>	<b>3,144</b>	<b>6,177</b>	<b>7,773</b>	<b>10,182</b>
Shareholder's a/c (INR m)	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Transfer from technical a/c	4,690	3,864	2,781	4,563	2,612	5,133	6,460	8,461
Income From Investments	2,074	2,360	3,212	3,143	3,943	3,860	4,527	5,206
<b>Total Income</b>	<b>6,781</b>	<b>6,351</b>	<b>6,033</b>	<b>7,858</b>	<b>6,858</b>	<b>9,296</b>	<b>11,289</b>	<b>13,970</b>
Other expenses	292	739	707	785	900	1,017	1,149	1,299
Contribution to technical a/c	410	502	1,168	1,999	2,210	2,400	2,600	2,800
<b>Total Expenses</b>	<b>701</b>	<b>1,241</b>	<b>1,874</b>	<b>2,784</b>	<b>3,110</b>	<b>3,417</b>	<b>3,749</b>	<b>4,099</b>
<b>PBT</b>	<b>5,978</b>	<b>5,102</b>	<b>4,170</b>	<b>5,069</b>	<b>3,749</b>	<b>4,480</b>	<b>7,540</b>	<b>9,871</b>
Prov for Tax	(585)	131	(303)	(694)	(152)	(450)	(452)	(592)
<b>PAT</b>	<b>5,394</b>	<b>5,232</b>	<b>3,867</b>	<b>4,374</b>	<b>3,597</b>	<b>4,030</b>	<b>7,088</b>	<b>9,279</b>
<b>Growth</b>	<b>-3%</b>	<b>-3%</b>	<b>-26%</b>	<b>13%</b>	<b>-18%</b>	<b>12%</b>	<b>76%</b>	<b>31%</b>
Balance sheet (INR m)	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Sources of Fund								
Share Capital	19,188	19,188	19,188	19,188	19,188	20,608	20,608	20,608
Reserves And Surplus	6,806	10,589	12,760	16,208	20,184	39,110	45,059	53,165
<b>Shareholders' Fund</b>	<b>25,739</b>	<b>30,079</b>	<b>31,959</b>	<b>35,467</b>	<b>39,983</b>	<b>60,396</b>	<b>66,420</b>	<b>74,608</b>
Policy Liabilities	4,54,807	5,58,936	6,72,822	8,05,354	9,73,550	11,68,260	14,01,911	16,82,294
Prov. for Linked Liab.	1,74,210	2,54,703	2,94,035	3,03,656	3,87,991	5,13,940	5,01,096	4,74,269
Funds For Future App.	30,962	29,819	32,369	35,803	38,727	42,600	46,860	51,546
Current liabilities & prov.	20,276	28,853	37,214	38,656	36,183	39,801	43,781	48,159
<b>Total</b>	<b>6,97,448</b>	<b>9,12,228</b>	<b>10,83,335</b>	<b>12,42,553</b>	<b>15,38,216</b>	<b>17,85,873</b>	<b>20,17,039</b>	<b>22,83,553</b>
Application of Funds								
Shareholders' inv	32,581	38,484	51,477	55,042	58,484	70,181	80,708	92,814
Policyholders' inv	4,60,484	5,81,847	6,89,187	8,21,021	10,08,078	12,09,694	13,91,148	15,99,820
Assets to cover linked liab.	1,91,642	2,83,736	3,34,432	3,52,502	4,41,793	4,68,300	4,96,398	5,26,182
Loans	4,264	5,322	6,661	9,248	10,605	16,225	24,825	37,982
Fixed Assets	2,187	2,213	2,604	3,452	4,153	4,859	5,685	6,652
Current assets	26,566	29,480	36,189	39,942	51,286	56,414	62,056	68,261
<b>Total</b>	<b>6,97,448</b>	<b>9,12,228</b>	<b>10,83,335</b>	<b>12,42,553</b>	<b>15,38,216</b>	<b>17,85,873</b>	<b>20,17,039</b>	<b>22,83,553</b>

## Financials and valuations

Operating ratios (%)	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Investment yield	3.3%	15.2%	9.0%	5.1%	12.4%	8.6%	7.8%	7.8%
<b>Commissions / GWP</b>	<b>6.3%</b>	<b>6.5%</b>	<b>6.3%</b>	<b>6.4%</b>	<b>8.1%</b>	<b>8.4%</b>	<b>8.5%</b>	<b>8.5%</b>
- first year premiums	-17.2%	-17.5%	-18.0%	-18.7%	-27.5%	-27.0%	-27.0%	-27.0%
- renewal premiums	-2.6%	-2.7%	-2.5%	-2.5%	-2.4%	-2.4%	-2.4%	-2.4%
- single premiums	-1.1%	-1.4%	-1.8%	-1.6%	-1.5%	-1.0%	-1.0%	-1.0%
Operating expenses / GWP	-14.5%	-14.2%	-13.5%	-14.1%	-13.8%	-14.0%	-13.9%	-13.8%
<b>Total expense ratio</b>	<b>-20.8%</b>	<b>-20.7%</b>	<b>-19.7%</b>	<b>-20.5%</b>	<b>-22.0%</b>	<b>-22.4%</b>	<b>-22.4%</b>	<b>-22.3%</b>
Claims / NWP	41.4%	37.4%	42.2%	40.1%	46.0%	41.5%	40.2%	40.3%
Solvency ratio	207%	202%	201%	193%	172%	201%	185%	185%
Persistency ratios (%)	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
13th Month	83.0%	84.0%	85.0%	84.0%	87.0%	88.0%	89.0%	90.0%
25th Month	71.0%	71.0%	68.0%	68.0%	70.0%	71.0%	72.0%	73.0%
37th Month	63.0%	63.0%	61.0%	62.0%	63.0%	63.5%	64.0%	64.5%
49th Month	59.0%	58.0%	56.0%	63.0%	66.0%	66.5%	67.0%	67.5%
61st Month	52.0%	54.0%	50.0%	58.0%	58.0%	58.5%	59.0%	59.5%
Profitability ratios (%)	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
New business margin (%)	21.6%	25.2%	27.4%	31.2%	26.5%	24.0%	25.0%	25.5%
RoE (%)	20.2%	18.7%	12.5%	13.0%	9.5%	8.0%	11.2%	13.2%
Operating RoEV	20.3%	18.6%	19.2%	22.1%	20.2%	19.1%	18.5%	18.4%
RoEV (%)	11.6%	18.6%	19.8%	14.7%	19.9%	29.2%	19.4%	19.2%
Valuation ratios	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Total AUM (INR b)	685	904	1,075	1,229	1,508	1,750	1,933	2,180
EPS (INR)	14.5	11.0	8.1	9.2	7.6	9.3	16.4	21.5
Value of new business (INRb)	9.0	12.5	15.3	19.5	19.7	21.1	25.3	30.0
Embedded Value (INR b)	99.8	118.4	141.8	162.6	194.9	251.9	300.9	358.6
EV Per share (INR)	209.7	248.7	297.9	341.8	409.7	584.2	697.7	831.5
P/EV (x) - after 20% holdco disc	8.0	6.7	5.6	4.9	4.1	2.9	2.4	2.0
P/EPS (x)	115.7	152.7	206.6	182.6	222.1	179.6	102.1	78.0
P/EVOP(x)	39.9	39.1	31.8	23.1	22.0	19.4	15.6	13.1
P/VNB(x)	80.7	58.0	47.4	37.1	36.7	34.4	28.6	24.1

*Note: Valuation ratios adjusted for MFS stake (80%) and hold company discount (20%)*

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analyst is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal Capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal Capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business transaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com).

Nainesh Rajani

Email: [nainesh.rajani@motilaloswal.com](mailto:nainesh.rajani@motilaloswal.com)

Contact: (+65) 8328 0276

#### Specific Disclosures

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months

- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

#### Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no warranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

#### Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN .: 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dgrievances@motilaloswal.com.